tetracycline and ferric-hydroxide

The study was carried out as an open-label, laboratory-blind, single-dose, randomized, two-period crossover, isotope efficacy study. Twenty-two patients with iron-deficiency anemia were enrolled in the study. The study consisted of two treatment phases of 15 days each, including blood sample measurements for Fe-59 activity. The two treatments were given orally. Treatment A was Fe-59 labeled iron(III)-hydroxide polymaltose complex (IPC, Maltofer) equivalent to 100 mg elemental iron given orally. Treatment B consisted of Fe-59 labeled IPC complex equivalent to 100 mg elemental iron and 500 mg tetracycline HCl (CAS 64-75-5) given orally. No differences between the two treatment groups with regard to the erythrocyte iron uptake were found, and thus IPC can be used with tetracycline, if necessary.

Topics: Adult; Anemia, Iron-Deficiency; Anti-Bacterial Agents; Chemical Phenomena; Chemistry, Physical; Cross-Over Studies; Dietary Supplements; Drug Interactions; Erythrocyte Indices; Erythrocytes; Female; Ferric Compounds; Ferritins; Hemoglobins; Humans; Iron; Iron Chelating Agents; Iron Radioisotopes; Male; Middle Aged; Prospective Studies; Quality Control; Sample Size; Single-Blind Method; Tetracycline

Naturally occurring Mn-rich limonite mainly composed of goethite and manganese oxides was used to remove tetracycline (TC) from the aqueous solution. The effects of dosage, initial solution pH, temperature, and coexisting anions on TC removal were investigated. Results showed that 95% of TC (30.0 mg·L

Topics: Adsorption; Anti-Bacterial Agents; Ferric Compounds; Hydrogen-Ion Concentration; Kinetics; Spectroscopy, Fourier Transform Infrared; Tetracycline; Water Pollutants, Chemical; Water Purification